PSYCHEDELIC DRUG DEVELOPMENT NEWS
Drug Developer Skips the Trip Entirely, Unveils Deuterium-Assisted Psychotherapy Candidate (Apr 1)
Initial reports describe the experience, though lacking psychedelics’ characteristic subjective effects, as “heavy” and “somewhat unstable”, but “noticeably patentable”.
Company Receives Notice of Allowance for U.S. Patent Covering Crystalline Polymorphs of Water (Apr 1)
The company announced the claims cover its lead candidate, Polymorph Eau.
Researchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.
Positive 3-year results from the phase III PHOTON study were presented at the recent American Academy of Ophthalmology (AAO) meeting, demonstrating that patients with diabetic
A study reveals olive oil wastewater extract enriched with hydroxytyrosol shows promise in preventing cardiovascular diseases through antioxidant properties.